Akèy › Sendwòm myelodisplastik › Ohio
Etid klinik pou Sendwòm myelodisplastik nan Ohio
22 etid pou Sendwòm myelodisplastik ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Cleveland Clinic, Cleveland
- The Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT05320198A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Cleveland clinic OH, Cleveland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07422480Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
Ap rekriteEtid obsèvasyon
2 Months · Tout sèks · Mizajou Sep 16, 2026 · NCT00900198Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06904482Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT03471260Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Ohio State University, The James Comprehensive Cancer, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06846606Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- ak 3 plis
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Gabrail Cancer Center Research, Canton
- Cleveland Clinic - Cleveland, Cleveland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06499285Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Cleveland Clinic, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT05308264A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- GSK Investigational Site, Canton
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 2, 2026 · NCT068478675-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
- Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou May 18, 2026 · NCT04187703A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- Ohio State University Medical Center, Columbus
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Mar 25, 2026 · NCT03533816A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04988555Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- Cleveland Clinic Cancer Center, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 5, 2026 · NCT06543381HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteFaz 2
3 Months · Tout sèks · Mizajou Nov 12, 2025 · NCT02143830SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT06501196HPC Offered for PRESERVE Expansion
- The Ohio State University Medical Center, Columbus
Ap rekriteEtid obsèvasyon
Laj 12 a 80 · Tout sèks · Mizajou Aug 28, 2025 · NCT07145411Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.